Evidence map›Paper›PMID 41952329›Full record

ArticleTransfusion2026

Rhesus blood group haplotype determination by nanopore sequencing and adaptive sampling enables the precise determination of complex allele combinations that could not be accurately determined by standard methods.

Rebekka Waldmann, Marita Führer, Annika Vogt, Dominik Nolde, Melanie Riecker, Lennart Finn Herrlich, Timo Dinse, Hubert Schrezenmeier, Christof Weinstock, David Alexander Christian Messerer

Abstract read
In one paragraph

Article in Transfusion, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rebekka WaldmannInstitute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Service Baden-Württemberg - Hessen and Ulm University Hospital, Ulm, Germany.
Marita FührerInstitute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Service Baden-Württemberg - Hessen and Ulm University Hospital, Ulm, Germany.
Annika VogtInstitute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Service Baden-Württemberg - Hessen and Ulm University Hospital, Ulm, Germany.
Dominik NoldeInstitute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Service Baden-Württemberg - Hessen and Ulm University Hospital, Ulm, Germany.
Melanie RieckerInstitute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Service Baden-Württemberg - Hessen and Ulm University Hospital, Ulm, Germany.
Lennart Finn HerrlichInstitute for Transfusion Medicine, Ulm University Hospital, Ulm, Germany.
Timo DinseInstitute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Service Baden-Württemberg - Hessen and Ulm University Hospital, Ulm, Germany.
Hubert SchrezenmeierInstitute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Service Baden-Württemberg - Hessen and Ulm University Hospital, Ulm, Germany.
Christof WeinstockInstitute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Service Baden-Württemberg - Hessen and Ulm University Hospital, Ulm, Germany.ORCID https://orcid.org/0000-0001-9739-8948
David Alexander Christian MessererInstitute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Service Baden-Württemberg - Hessen and Ulm University Hospital, Ulm, Germany.ORCID https://orcid.org/0000-0002-0834-038X

Funding

German Red Cross Blood Service Baden-Württemberg - Hessen F+E_2023_007
6 · The paper itself

Abstract

backgroundPatients with chronic transfusion needs such as those with sickle cell disease face a high risk of developing antibodies against high-prevalence antigens in the RH blood group system, complicating transfusion therapy and potentially necessitating stem cell transplantation. Molecular characterization of the RH system is hindered by hybrid alleles and high sequence homology between RHD and RHCE, limiting the effectiveness of conventional short-read sequencing. STUDY DESIGN AND

methodsWe analyzed 11 control and 20 patient samples, some of which could not be reliably genotyped by standard methods.

resultsNanopore sequencing with adaptive sampling enables targeted, amplification-free long-read sequencing of the RH locus, resolving homologous and complex hybrid structures and enabling complete haplotype phasing for all samples, including samples that could not be accurately determined by standard methods like serology and short-read sequencing. Four new alleles were identified and for 13 out of 20 patients the results led to a change in the transfusion regimen. DISCUSSION: These findings show that nanopore sequencing with adaptive sampling allows unambiguous genotyping of the RH system, improves detection of complex variants, and supports better-matched transfusion strategies for chronically transfused patients.

Indexed as

Nanopore SequencingRh-Hr Blood-Group SystemAllelesBlood DonorsBlood Grouping and CrossmatchingBlood TransfusionHaplotypesHumansRh-Hr Blood-Group System

Identifiers

PMID41952329
PMCPMC13250356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.